Clinical Characteristics, Management, and Outcomes of Intramedullary Spinal Cord Ependymomas: A Systematic Review and Meta-Analysis

脊髓内室管膜瘤的临床特征、治疗和预后:系统评价和荟萃分析

阅读:1

Abstract

INTRODUCTION: Intramedullary spinal cord tumors (IMSCTs) are rare tumors, with ependymoma being the most common type. Surgical resection is the main treatment, but gross total resection (GTR) carries a risk of morbidity, while subtotal resection (STR) increases the risk of recurrence. The role of adjuvant radiotherapy is debated, and chemotherapy is rarely used except for recurrence. This study aims to investigate and compare the clinical characteristics, management, and outcomes of intramedullary spinal cord ependymomas (ISCEs) comprehensively. METHODS: This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, analyzing clinical characteristics, management, and outcomes of ISCEs. Studies were screened using Population, Intervention, Comparison, Outcome, and Study design criteria, quality-assessed with Newcastle-Ottawa Scale and Risk Of Bias In Non-randomized Studies Of Interventions, and statistically analyzed with Review Manager 5.4.1 and R software, evaluating treatment efficacy and prognostic factors. RESULTS: GTR improves neurological function, reduces recurrence, and improves survival in IMSCTs, while STR increases the risk of recurrence, which often requires radiotherapy. The meta-analysis indicates that patients who received optimal management strategies had significantly better neurological outcomes (odds ratio: 4.65; 95% confidence interval: 1.77-12.23; p=0.0018). Meta-analysis also showed that based on the management approach, the rate of complication, improvement, recurrence, and overall survival was 16%, 71%, 7%, and 18%, respectively. CONCLUSIONS: Surgical strategies, individualized treatment, and advanced monitoring optimize IMSCT outcomes. Future research should standardize protocols, conduct large-scale studies, and refine adjuvant therapies to improve prognosis and quality of life.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。